The neurodevelopmental spectrum of CASK-related disorder

- 2 Jessica Martin¹, Alkistis Mavrogalou-Foti¹, Josefine Eck¹, Laura Hattersley², Kate Baker^{1, 3, 4}
- 3 ¹ MRC Cognition and Brain Sciences Unit, University of Cambridge
- 4 ² CASK Research Foundation
- 5 ³ Department of Medical Genetics, University of Cambridge
- 6 ⁴ Department of Pathology, University of Cambridge
- 7 *Correspondence to Kate Baker: <u>kate.baker@mrc-cbu.cam.ac.uk</u>

Abstract

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

Background: Pathogenic CASK variants are associated with neurodevelopmental disorders of variable severity including X-linked intellectual disability (XLID) and microcephaly with pontocerebellar hypoplasia (MICPCH). Although the number of diagnosed cases is rising, current understanding of the CASK-related neurodevelopmental spectrum is limited. Here, we systematically review the published characteristics of individuals with CASK-related disorder, and compare these to a more recently-diagnosed group. We provide quantitative information about the ranges of adaptive abilities, motor function, visual function and social-emotional-behavioural characteristics, and explore within-group associations. Methods: 151 individuals with CASK variants were identified in published literature. 31 children and young people with CASK variants were recruited to the UK-based Brain and Behaviour in Neurodevelopmental disorder of Genetic Origin (BINGO) project. BINGO-participating caregivers completed a bespoke medical history questionnaire and battery of standardised neurodevelopmental measures. Results: Comparing the recently diagnosed BINGO CASK-related disorder group to previously reported individuals, we found consistent prevalence of tone abnormalities, sensorineural hearing loss and epilepsy, but lower prevalence of severe/profound ID, MICPCH, optic atrophy and nystagmus. Areas of frequent difficulty not highlighted in previous reports include sleep difficulties and cerebral visual impairment (CVI). Neurodevelopmental characteristics were highly variable within the BINGO CASK-related disorder group, and group-wide patterns were similar to those observed in other rare genetic conditions. Within the BINGO CASK-related group, epilepsy is significantly associated with ID severity, after controlling for age. Sub-groups with MICPCH or microcephaly only have equivalent ranges of adaptive function, but MICPCH may be associated with more severe motor difficulties.

- 32 Conclusion: The spectrum of neurodevelopmental characteristics associated with CASK-related
- 33 disorder appears to be broadening with increased access to genome-wide diagnostic testing.
- 34 Further studies are needed to elucidate the relationships between CASK variants, structural brain
- development, epilepsy, and neurodevelopmental characteristics.

Keywords

36

- 37 CASK-related disorder, X-linked Intellectual Disability, MICPCH, Epilepsy, Autism characteristics,
- 38 Adaptive function, Cerebral Visual Impairment, Genetic, Sleep difficulties

Background

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

Calcium/calmodium-dependent serine protein kinase (CASK) is a multi-domain scaffolding protein and a member of the membrane-associated guanylate kinase (MAGUK) family, with diverse neuronal functions (reviewed in 1). Several neurodevelopmental presentations have been reported in association with CASK variants including: X-linked intellectual disability (XLID) (2,3), microcephaly with pontine and cerebellar hypoplasia (MICPCH) (4-6), XLID with or without nystagmus and microcephaly (7,8), X-linked optic and ophthalmic problems (9), and FG syndrome (10,11). Prior to next generation sequencing (NGS) diagnostics, most individuals with CASK-related diagnoses were identified phenotype-first based on these descriptions. With the application of genotype-first NGS diagnostic approaches and broader ascertainment of individuals with neurodevelopmental presentations for clinical genetic testing, the number of individuals diagnosed with a CASK-related disorder is rising. Consequently, the reported CASK-associated phenotypic spectrum may not be fully representative. There is an urgent need for an up-to-date phenotypic evidence base which can contribute to variant interpretation and provide accurate information about the nature and range of long-term challenges faced by this patient group. In particular, there has been limited characterisation of cognitive, adaptive, behavioural and socialemotional functions within CASK-related disorder. Almost all reported individuals have developmental delay and intellectual disability (ID) (12), and there have been several reported cases of autism spectrum disorder (ASD) and autism-related traits (13–16). However, no systematic evaluation of neurodevelopmental domains has been published. Standardised measures of motor function, communication and social-emotional functions appropriate for individuals with ID have not been included within any case series. Additionally, the factors predicting neurodevelopmental variation within CASK-related disorder are unclear. Truncating and missense variants have been associated with more severe and less severe presentations respectively, with males being more severely affected than females within either

variant group (12). However, there are exceptions to this pattern, such as a nonsense variant identified in a mildly affected male patient (14) and missense variants identified in severely affected females (17,18). Moreover, gender and variant type cannot enable precise predictions of ID severity, because the majority of CASK-diagnosed individuals are female and have truncating variants. Beyond genotype, the presence and extent of neuroanatomical abnormalities could be another predictor of neurodevelopmental variation. For example, a relationship has been observed between more severe MRI findings (i.e., MICPCH) and a more severe clinical presentation (i.e., epilepsy, ophthalmologic, motor and speech problems), in males but not females with CASK variants (19,20). Another potential within-group influence on neurodevelopment could be epilepsy, which affects around 50% of individuals with a CASK variant (21,22), and can predict developmental abilities in other monogenic conditions (23–26). One preliminary study in CASK-associated disorder did not find evidence for a link between epilepsy characteristics and severity of developmental delay (21), but variant type and gender may be confounding factors. In this paper, we aim to address these gaps and provide a comprehensive phenotypic description of CASK-related disorder. First, we present a structured review of published clinical case series, to provide a benchmark for comparison to 31 individuals with CASK variants assessed via a structured parent-report questionnaire within a wider research study (BINGO - Brain and Behaviour in Neurodevelopmental disorders of Genetic Origin). This comparison enables us to establish whether the CASK-related phenotypic spectrum is changing in parallel with broader ascertainment and genotype-first diagnostics. Second, we present standardised multi-domain neurodevelopmental data for the BINGO CASK participant group, to document their range of abilities and difficulties, including relationships between domains. Third, we explore whether neurodevelopmental variation within this group is associated with neuroanatomical abnormalities or epilepsy.

Methods

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

Literature Review

We conducted a review of literature describing the clinical features of individuals with *CASK*-related disorder. Relevant literature published up until May 2024 was identified on Medline (PubMed) and Google Scholar using the search terms "*CASK*", "*CASK*-related disorders", "microcephaly", "MICPCH", and "pontocerebellar hypoplasia". Additional papers were identified from bibliographies. We included case series that reported (A) at least three individuals with *CASK*-related disorder who had not been previously described and (B) clinical characteristics assessed via direct evaluation or retrospective review of available medical records. Using these inclusion criteria, we identified 15 papers. We excluded Hayashi et al. (2012)(4) from the review as all individuals were later described in Takanashi et al., (2012)(27). Individuals previously described in Valayannopoulos et al., (2012)(28) and Takanashi et al., (2012)(27) were also excluded from our summary of Burglen et al., (2012)(19) and Hayashi et al., (2017)(5), respectively. Thus, our review includes 14 papers and, to the best of our knowledge, summarises unique individuals with *CASK*-related disorder.

BINGO data collection

Participants

Children and young people (CYPs) with *CASK*-related disorder were recruited to BINGO via an international network of *CASK*-related charities (*CASK* Research Foundation, Angelina *CASK* Neurological Research Foundation, Association Enfants *CASK* France), UK-based charities for rare conditions (Unique, Cambridge Rare Disease Network, Genetic Alliance UK), and regional genetic services in the UK. CYPs were eligible if they were aged at least 3 years old, experienced neurodevelopmental difficulties, and had a pathogenic or likely pathogenic *CASK* gene variant, or a variant of uncertain significance, which was previously fed-back via a clinical genetic services as likely related to clinical presentation. Genetic diagnoses were confirmed via medical records. *CASK* variants were classified as single nucleotide variants (SNVs) or copy number variants (CNVs). SNVs were annotated as either (a) protein-truncating, (b) intronic or (c) missense variants; CNVs were

annotated as either (a) intragenic or (b) multi-gene in line with previous literature on pathogenic *CASK* genotypes.

Phenotyping methods

Parent-report questionnaires were completed online, by post, or via Zoom or telephone interview according to parent preference. Clinical information was gathered via a study-specific medical history questionnaire (MHQ) covering prenatal, infancy and childhood health, plus acquisition of developmental milestones. Information regarding structural brain abnormalities was obtained via Magnetic Resonance Imaging reports (MRI; n = 14), genetic test reports (n = 9) and parental reports (n = 2). Standardised neurodevelopmental questionnaires and procedures for scoring and analysis are described in Supplementary Table 1.

Statistical analysis

BINGO data were analysed using R studio, version 2023.3.0.386. Where participants had partial datasets, all available data were included in analyses. Raincloud plots were generated for each questionnaire measure. Cut-off scores were overlaid on each raincloud plot where possible to contextualise the severity of difficulties in *CASK*-related disorder relative to normative populations, or previously reported literature. Within-sample relationships were explored between demographic (age, sex), neurological (epilepsy), developmental (Vinland Adaptive Behaviour Scales (VABS; 29) composite score, Flemish Cerebral Visual Impairment Questionnaire (FCVIQ; 30) total score, and social-emotional-behavioural (total scores on the Social Responsiveness Scale (SRS-2; 31), the Developmental Behaviour Checklist (DBC2; 32), and the Repetitive Behaviour Questionnaire (RBQ; 33)) characteristics using statistical tests appropriate to data type. Non-parametric methods were selected if data violated the assumption of normality, and Kendall's tau correlation was chosen over Spearman's rank correlation if ties represented more than 20% of the data. To reduce the likelihood of type I errors, p-values were adjusted for multiple testing by applying a Benjamini-Hochberg False Discovery Rate (B-H FDR) correction. Regression analyses were used to examine the influence of

epilepsy on adaptive function (VABS composite score). The assumptions of regression were tested prior to analyses (Supplementary Table 6a and 7a). Descriptive differences were explored between CYPs with different neuroanatomical abnormalities (MICPCH vs. microcephaly only vs. no abnormalities reported). Variables explored were demographic characteristics, VABS composite scores and VABS motor domain scores, FCVIQ total scores and epilepsy prevalence.

Results

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

Review of published cases

Supplementary Table 2 summarises the clinical characteristics of 151 individuals carrying CASK variants, reported in previous publications. The majority were female (72.2%) and age ranged from 2 weeks to 49 years old at the time of reporting. SNVs accounted for 71.5% of CASK variants, encompassing protein-truncating (44.4%), intronic (35.2%), and missense (20.4%) variants. CNVs (28.5%) included both intragenic (48.8%) and multi-gene (51.2%) deletions of varying sizes. De novo variants (77.3%) were more common than inherited variants (22.7%). The most frequently reported clinical problems were feeding difficulties (57.1%), including gastroesophageal reflux, sucking and swallowing difficulties. Interventions such as thickened liquids/pureed foods, nasogastric tube or gastrostomy were common, although feeding difficulties were noted to improve with age in some individuals (1,20). Tone abnormalities were also frequent, including hypotonia (57.1%), hypertonia (41.8%) or mixed tone abnormalities (14%). Epilepsy was reported in 48.9% overall. Seizure details were inconsistently reported, but a range of seizure types were described, including early infantile epileptic encephalopathies with variable EEG phenotypes (e.g., West Syndrome, Ohtahara syndrome), infantile spasms, later-onset epilepsies (generalised or focal) and myoclonic epilepsies. Many individuals had mixed seizure types and there was a variable response to anti-seizure medications from remission to intractable. Optic atrophy (28.6%), strabismus (30.4%) and nystagmus (25%) were common ophthalmological abnormalities co-

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

occurring with each other. Other reported vision-related phenotypes included astigmatism, myopia, hyperopia, retinopathy, glaucoma and cerebral visual impairment (CVI). Sensorineural hearing loss was present in 24.6%. Other characteristics less frequently reported were scoliosis, kidney problems and sleep disturbances. The majority of reported individuals with CASK-related disorder had severe or profound developmental delay (88%). 56.6% were able to sit without support and acquired this ability between 6 months and 3 years. Fewer individuals (25.7%) had acquired the ability to walk independently with age of acquisition ranging from 18 months to 6 years. There were also three reports of regression of motor abilities, including a case of mild regression at 2 years (6), an individual that lost ability to walk at 25 years after severe febrile seizures (1), and an individual that lost ability to sit after scoliosis surgery (14). A minority of individuals were reported to use some vocal communication (33.8%), which ranged from babbling and vocalisations to short sentences. Two papers reported individuals using Augmentative and Alternative Communication (AAC) systems as non-verbal methods of communication, such as an eye gaze device and Picture Exchange Communication System (PECS; 14,19). In the papers we identified, there was a limited focus on social, emotional and behavioural problems with only four papers describing social or emotional-behavioural difficulties, such as ASD (1,14), selfinjurious behaviours (19) and general behavioural difficulties (28). Where MRI data were reported, the majority of individuals with CASK variants had MICPCH (87.1%). There were also five individuals with cerebellar and/or pontine hypoplasia only (3.6%), four individuals with microcephaly and other brain abnormalities (2.9%), three cases of microcephaly with cerebellar hypoplasia only (2.1%), three of microcephaly only (2.1%), and three reports of no brain abnormalities (2.1%).

Comparison between reviewed cases and BINGO CASK-related group

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

Thirty-one CYPs with CASK-related disorder participated in BINGO and were included in this analysis. Comparison between demographic and clinical characteristics of BINGO participants and the reviewed population is summarised in Table 1. A higher proportion of the BINGO group were female, and the age range was narrower due to an age limit for BINGO eligibility. The proportion of individuals with either CASK SNVs or CNVs were near identical between reviewed cases and BINGO, although the BINGO group contained a higher proportion of truncating SNVs versus missense SNVs, and higher proportion of intragenic versus multi-gene CNVs. There were fewer reports of MICPCH in the BINGO group (44.0% vs. 87.1%) and more reports of microcephaly only (32.0% vs. 2.1%). A higher percentage of feeding difficulties was reported in BINGO (83.9% vs. 57.1%), but the range of difficulties and interventions reported were similar to the reviewed group. The frequency of reported tone abnormalities, sensorineural hearing loss and epilepsy were comparable between the BINGO group and reviewed group. A range of seizure types were reported in BINGO, including infantile spasms, myoclonic epilepsies, as well as focal, complex and absence seizures. The age of seizure onset varied from 4 months to 10 years. Reports of strabismus, refractive errors and CVI were similar between BINGO and reviewed cases, but optic atrophy and nystagmus were not common in the BINGO group (9.7% and 3.2%, respectively) compared to reviewed cases (28.6% and 25%, respectively). Sleep difficulties were common in our sample (74.12% ever experienced) but were not widely reported in previous literature (see 19 for exception). Parents reported a range of sleep-associated problems including difficulty settling, regular waking, and need for more or less sleep than expected for age, as well as sleep apnoea. There were notable differences between BINGO and the reviewed group in acquisition of developmental milestones, whereby a higher percentage of the BINGO group had acquired the ability to sit (87.1% vs. 56.6%) and walk (51.6% vs. 25.7%). Reported verbal abilities were similar across the two groups. Categorisation of ID severity also differed between groups, with a higher percentage of the BINGO group in the mild or moderate (60.7% vs. 12.0%) rather than severe (25.0%

vs. 75.0%) category, noting that this categorisation was based on VABS data in BINGO but clinical report in the reviewed sample.

213 INSERT TABLE 1

Neurodevelopmental variation within the BINGO CASK-related group

Figures 1-5 show the distribution of scores on neurodevelopmental and social-emotional-behavioural measures. VABS composite scores indicated that global adaptive ability ranged from mildly impaired to severely/profoundly impaired (Figure 1). Communication was the most affected subdomain, whereas Socialisation was a relative strength.

219 INSERT FIGURE 1

Scores on the SRS-2 revealed high levels of autism-related traits, varying in severity within the atypical range. CYPs with *CASK*-related disorder demonstrate relative strengths in social motivation on the SRS-2, compared to other social subscales or Restricted and Repetitive Behaviours (Figure 2). These patterns are overall similar to observations in other rare genetic conditions (34,35). The majority of DBC2 scores were in the moderate-serious concerns range (Figure 3), with relatively greater difficulties with self-absorbed behaviour (a DBC-2 subscale involving diverse items including mouthing objects, special interests and stereotyped behaviours). On the RBQ, the majority of participants scored above the threshold for 'normal' levels of repetitive behaviours, and scored relatively higher on the stereotyped subdomain (Figure 4). Challenging Behaviour Questionnaire (CBQ, 36) reported rates of self-injury (42.86%), physical aggression (46.43%) and stereotyped behaviour (50.00%) were high (Supplementary Table 3), but similar to rates observed in other rare neurogenetic conditions (37,38). The severity of these behaviours also varied, but on average was similar to those reported in individuals with other rare neurogenetic conditions (39).

233 INSERT FIGURE 2

234 INSERT FIGURE 3

235 INSERT FIGURE 4

The majority of CYPs with CASK-related disorder are at risk of CVI, according to FCVIQ Sum Scores (*M* = 5.10, *SD* = 1.21, range: 2-6; 90% above cut-off score of 4). Factor scores on the FCVIQ show that the BINGO CASK-related group experienced difficulties with object and face processing, visual interest, moving in space and anxiety-related behaviours of a level comparable to children with CVI, whereas clutter and distance viewing might be relatively spared (Figure 5). Broadening to other aspects of sensory development, most participants scored within the 'like the majority of others' range on the Seeking and Avoiding subdomains of the Short Sensory Profile (SSP-2; 40) (Supplementary Table 4), but within the 'more than others' and the 'much more than others' range on the Sensitivity and Registration subdomains, respectively. The majority of participants also scored within the 'more than others' and the 'much more than others' ranges on the sensory and behavioural section of the SSP-2, indicating that CYPs with CASK-related disorder display more sensory-related behaviours than most children.

248 INSERT FIGURE 5

Associations within the BINGO CASK-related group

Figure 6 and Supplemental Table 5 show the statistical relationships between demographic, neurological, developmental and social-emotional-behavioural characteristics within *CASK*-related disorder. We found moderate positive correlations between reversed VABS composite scores and (1) age ($r_s = 0.78$, p.adj < .01), and (2) epilepsy ($r_{pb} = 0.55$, p.adj = .03). We also found a moderate positive correlation between total scores on the DBC2 and RBQ ($\tau = 0.55$, p.adj < .01). No other relationship survived the B-H FDR correction for multiple testing.

256 INSERT FIGURE 6

When exploring factors that might contribute to neurodevelopmental variation within *CASK*-related disorder, we found epilepsy was a significant predictor of adaptive ability (F(1, 25) = 10.69, p < .001),

and explained approximately 27% of the variance in adaptive ability (Supplementary Table 6b). We also examined whether entering age as a predictor into this model would affect the relationship between epilepsy and adaptive ability, as we found age was significantly positively correlated with adaptive ability. The overall model was significant (F(2, 24) = 16.38, p < .001) and explained approximately 54% of the variance in adaptive ability. As shown in Supplementary Table 7b, epilepsy remained a significant independent predictor of adaptive ability ($\beta = 11.00$, p = .032) and age was also a significant independent predictor of adaptive ability ($\beta = 1.56$, p < .001). In addition to epilepsy, available data facilitated descriptive exploration of whether neuroanatomical abnormalities might contribute to neurodevelopmental variation within CASK-related disorder. For the purposes of this analysis, we combined MRI findings into three categories: MICPCH (i.e., individuals with reported microcephaly and pontocerebellar abnormalities), Microcephaly (i.e., individuals with reported microcephaly but without reported pontocerebellar abnormalities), and Normal (i.e., individuals without reported microcephaly or neuroanatomical abnormalities). Individuals for whom no brain abnormality data were available, were classified as NA. Groups were not large-enough for statistical analysis, however, as shown in Supplementary Table 8, average scores on the VABS composite were similar between individuals with MICPCH (M = 40.15) and microcephaly only (M = 43.62), but average scores on the motor subdomain of the VABS differed, whereby individuals with MICPCH scored lower (M = 30.54) than individuals with microcephaly only (M = 46.88). Parent-reported epilepsy was also more common in individuals with MICPCH (53.85%) than microcephaly only (33.33%). Only two individuals were documented as having no neuroanatomical abnormalities, hence comparison to this group is not warranted.

Discussion

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

Previous studies of *CASK*-related disorder are largely based on retrospective medical reports of individuals identified phenotype-first, with few involving real-time assessments of developmental ability or social-emotional-behavioural symptoms. To overcome these knowledge gaps for the

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

current and future population of individuals diagnosed with CASK-related disorder, we first carried out a comprehensive review of the published clinical characteristics and compared prevalence rates to a more recently diagnosed group of CYPs with CASK variants (> 60% diagnosed after 2015). We then evaluated the range of developmental abilities and social-emotional-behavioural problems within this group, using standardised measures validated for individuals with ID. Lastly, we explored potential predictors of neurodevelopmental variation within CASK-related disorder, to identify possible markers of prognosis, or mediators of developmental trajectory. Comparison of the BINGO CASK-related group to previous literature provides preliminary evidence for an expanding CASK-related phenotype. A lower frequency of developmental delay, severe ID, and characteristics previously considered typical for CASK-related disorder (e.g., MICPCH, optic atrophy, nystagmus) were observed in the BINGO group, suggesting the within-group distribution of neurodevelopmental impairments has shifted to include individuals with less severe presentations. These differences could be attributed to sample ascertainment and measurement. CYPs in BINGO were recruited genotype-first, with broad inclusion criteria, reflecting identification of patients in clinical settings i.e. genetic testing for a wide range of developmental concerns, rather than discreet neuroanatomical or ophthalmological diagnoses. Assessment of ID severity varies between medical centres and countries due to differing guidelines and practice. Similarly, accessibility of neuroimaging and reporting of neuroradiological assessments is inconsistent. Adoption of standardised measures, like the VABS in this study, or routine assessment of neuroanatomy could help progress our understanding of CASK-related characteristics across cohorts and time. Nevertheless, the clinical spectrum of CASK-related disorder within BINGO may more closely reflect the currently-diagnosed CASK-related disorder population. We also identified characteristics associated with CASK-related disorder not highlighted in previous case series, which may require increased clinical attention. For example, sleeping difficulties, such as regular night waking and difficulty settling, were commonly reported in our sample of CYPs with

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

CASK-related disorder, but were not described in previous literature (with the exception of 19). Specific sleep disorders, along with poor sleep quality, timing, and duration, are common in individuals with ID and rare genetic syndromes (41-43), and parents of individuals with rare genetic conditions frequently highlight sleep as a significant area of concern (44,45). Moreover, poor sleep can be associated with poor adaptive abilities (46,47) and increased challenging behaviour (48-50). As such, it is possible that poor sleep might contribute to observed adaptive and social-emotionalbehavioural difficulties in CYPs with CASK-related disorder. However, the assessment of sleep difficulties in this study was limited and future studies should strive to generate objective descriptions of sleep difficulties and specific sleep disorders, as well as factors contributing to sleep disturbance such as pain or epilepsy, which are imperative for effective management. We also found that the majority of CYPs with CASK-related disorder were at risk of CVI (according to FCIVQ Sum Scores), however clinical assessments are needed to confirm these findings as only 5 participants in this sample had parent-reported CVI. CVI has been commonly reported in other monogenic conditions with similar genotypic or phenotypic characteristics (51,52). There is a strong association between CVI and seizures across monogenic conditions, in particular infantile spasms (52). This may be particularly relevant for CASK, as infantile spasms are the most common seizure type within the group (21). Despite high levels of difficulties across adaptive and social-emotional-behavioural measures, few significant relationships between measures were identified in the BINGO group of CYPs with CASKrelated disorder. In other words, difficulties in one developmental dimension do not necessarily go alongside difficulties in another dimension, and categorisation of individuals with CASK-related disorder as being mildly or severely affected overall may be overly simplistic. A lack of association could suggest that different characteristics, for example autism-related traits and CVI, might be unique dimensions of neurodevelopmental variability in CASK-related disorder. However, we only examined the relationships between total scores on these measures and it is possible that

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

subdomains of autism-related traits and CVI, or specific adaptive functions and challenging behaviours, might be related. Further analysis of the relationships between dimensions using additional methods, in a larger CASK-related group and over time, are necessary to understand potential developmental links. Prognostic markers of developmental ability are of interest to parents and clinicians in order to plan support needs and consider potential interventions. We found that the presence of epilepsy predicts poorer adaptive ability in CASK-related disorder. One possible interpretation is that seizure activity negatively impacts cognitive development in CASK-related disorder, a relationship also observed in other rare genetic conditions (23-26). Alternatively, epilepsy and poorer adaptive ability might both reflect altered trajectories of brain development, but are not causally related to one another. Moreover, anti-seizure medication has been associated with cognitive dysfunction, but evidence of these effects are mixed in part because of heterogeneities within the paediatric epilepsy population (53,54). To better understand the possible effects of epilepsy and its treatments on other aspects of CASK-related disorder, neurological data adopting standardised International League Against Epilepsy classification (55) and quantification of epilepsy severity and medication use plus longitudinal assessment of cognitive functions are required. In contrast, we did not find descriptive differences in global adaptive ability between individuals with MICPCH and microcephaly only. This may suggest that cortical abnormalities, rather than hindbrain abnormalities, contribute to developmental delay and cognition in CASK-related disorder. This is inconsistent with the previous presumption that individuals with MICPCH will be more severely affected (12,20). However, we observed poorer average motor abilities in CYPs with MICPCH than those with microcephaly only, confirming contribution of cerebellar abnormalities to motor development. These findings are observational and MRI data was limited (only available for 50% of the BINGO CASK-related disorder sample). Future studies with comparable MRI data are needed to

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

statistically interrogate the relationships between neuroanatomical abnormality neurodevelopmental dimensions in CASK-related disorder. Conclusions In conclusion, we provide an up-to-date description of the characteristics associated with CASKrelated disorder, which includes a diverse range of clinical features, developmental abilities and social-emotional-behavioural characteristics. We suggest that the group-wise distributions of ID severity, neuroanatomical features and ophthalmological abnormalities are expanding with broader ascertainment of individuals with CASK variants. The relationships between structural brain development, epilepsy and developmental trajectories warrant further investigation in this group. **Abbreviations** AAC: Augmentative and Alternative Communication ASD: Autism Spectrum Disorder B-H FDR: Benjamini-Hochberg False Discovery Rate **BINGO:** Brain and Behaviour in Neurodevelopmental disorder of Genetic Origin CASK: Calcium/calmodium-dependent serine protein kinase **CNV:** Copy Number Variant CYP: Children and Young People CVI: Cerebral Visual Impairment **DBC2:** Developmental Behaviour Checklist, Second Edition FCVIQ: Flemish Cerebral Visual Impairment Questionnaire ID: Intellectual Disability

379

381

383

384

385

386

387

388

389

391

394

395

396

399

MAGUK: Membrane-associated Guanylate Kinase 380 MHQ: Medical History Questionnaire MICPCH: Microcephaly and pontine cerebellar hypoplasia 382 MRI: Magnetic Resonance Imaging NGS: Next Generation Sequencing **PECS:** Picture Exchange Communication System **RBQ:** Repetitive Behaviour Questionnaire SNV: Single Nucleotide Variant **SRS-2:** Social Responsiveness Scale, Second Edition VABS: Vineland Adaptive Behaviour Scale XLID: X-linked Intellectual Disability **Declarations** 390 Availability of data and materials 392 Anonymised data may be made available to other researchers from the corresponding author on 393 reasonable request, and on condition of signing a Code of Conduct guaranteeing that the data will be kept confidential and securely. Ethics declarations Ethics approval and consent to participate 397 Study protocol was approved by the Cambridge Central Research Ethics Committee (IRAS reference: 398 11/EE/0330, 'Phenotypes in Intellectual Disability'), and written informed consent was obtained from each participant's parent/caregiver prior to inclusion.

400 Consent for publication 401 Not applicable 402 Competing interests 403 The authors declare no competing interests. 404 Acknowledgements 405 We thank all of the children and young people with CASK-related disorder and their families for their 406 participation in the BINGO project. We thank the charities who supported our research and 407 recruitment of participants into the BINGO project, in particular CASK Research Foundation, Angelina 408 CASK Neurological Research Foundation, Association Enfants CASK France, Unique, Cambridge Rare 409 Disease Network, and Genetic Alliance UK. **Funding** 410 411 This study was funded by the Medical Research Council (MC UU 00030/3), Great Ormond Street 412 Hospital Charity, and Cambridge NIHR Biomedical Research Centre. **Author Information** 413 **Authors and Affiliations** 414 415 MRC Cognition and Brain Sciences Unit, University of Cambridge, 15 Chaucer Road, Cambridge, 416 Cambridgeshire CB2 7EF 417 Jessica Martin, Alkistis Mavrogalou-Foti, Josefine Eck, Kate Baker 418 CASK Research Foundation, 33 Finchdean Road, Rowlands Castle, Hampshire PO9 6DA 419 Laura Hattersley 420 Department of Medical Genetics, University of Cambridge, Addenbrooke's Treatment Centre, 421 Cambridge Biomedical Campus, Cambridge, Cambridgeshire CB2 0QQ 422 Kate Baker

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

Department of Pathology, University of Cambridge, Tennis Court Road, Cambridge, Cambridgeshire CB2 1QP Kate Baker Contributions JM and KB designed and conceptualised the study, with assistance of LH. JM led data collection, supported by AMF and JE. Data analysis and the literature review were conducted by JM and AMF. JM wrote the first draft of the manuscript. AMF wrote parts of the manuscript. KB provided supervision, and reviewed and edited the manuscript. All authors read and approved the final manuscript. References Pan YE, Tibbe D, Harms FL, Reißner C, Becker K, Dingmann B, et al. Missense mutations in CASK, coding for the calcium-/calmodulin-dependent serine protein kinase, interfere with neurexin binding and neurexin-induced oligomerization. J Neurochem. 2021 May;157(4):1331–50. 2. Froyen G, Van Esch H, Bauters M, Hollanders K, Frints SGM, Vermeesch JR, et al. Detection of genomic copy number changes in patients with idiopathic mental retardation by high-resolution X-array-CGH: important role for increased gene dosage of XLMR genes. Hum Mutat. 2007 Oct;28(10):1034-42. Hayashi S, Mizuno S, Migita O, Okuyama T, Makita Y, Hata A, et al. The CASK gene harbored in a deletion detected by array-CGH as a potential candidate for a gene causative of X-linked dominant mental retardation. Am J Med Genet A. 2008 Aug 15;146A(16):2145-51. Hayashi S, Okamoto N, Chinen Y, Takanashi J ichi, Makita Y, Hata A, et al. Novel intragenic duplications and mutations of CASK in patients with mental retardation and microcephaly with pontine and cerebellar hypoplasia (MICPCH). Hum Genet. 2012 Jan;131(1):99–110.

446 Hayashi S, Uehara DT, Tanimoto K, Mizuno S, Chinen Y, Fukumura S, et al. Comprehensive 447 investigation of CASK mutations and other genetic etiologies in 41 patients with intellectual 448 disability and microcephaly with pontine and cerebellar hypoplasia (MICPCH). Bardoni B, editor. 449 PLOS ONE. 2017 Aug 7;12(8):e0181791. 450 Najm J, Horn D, Wimplinger I, Golden JA, Chizhikov VV, Sudi J, et al. Mutations of CASK cause an 451 X-linked brain malformation phenotype with microcephaly and hypoplasia of the brainstem and 452 cerebellum. Nat Genet. 2008 Sep;40(9):1065-7. 453 Hackett A, Tarpey PS, Licata A, Cox J, Whibley A, Boyle J, et al. CASK mutations are frequent in 454 males and cause X-linked nystagmus and variable XLMR phenotypes. Eur J Hum Genet. 2010 455 May;18(5):544-52. 456 Tarpey PS, Smith R, Pleasance E, Whibley A, Edkins S, Hardy C, et al. A systematic, large-scale 457 resequencing screen of X-chromosome coding exons in mental retardation. Nat Genet. 2009 458 May;41(5):535-43. 459 Dimitratos SD, Stathakis DG, Nelson CA, Woods DF, Bryant PJ. The Location of HumanCASKat 460 Xp11.4 Identifies This Gene as a Candidate for X-Linked Optic Atrophy. Genomics. 1998 461 Jul;51(2):308-9. 462 10. Dunn P, Prigatano GP, Szelinger S, Roth J, Siniard AL, Claasen AM, et al. A de novo splice site 463 mutation in CASK causes FG syndrome-4 and congenital nystagmus. Am J Med Genet A. 2017 464 Mar;173(3):611-7. 465 11. Piluso G, D'Amico F, Saccone V, Bismuto E, Rotundo IL, Di Domenico M, et al. A Missense 466 Mutation in CASK Causes FG Syndrome in an Italian Family. Am J Hum Genet. 2009 467 Feb;84(2):162-77.

12. Moog U, Kutsche K. CASK Disorders. In: GeneReviews® [Internet] [Internet]. Seattle (WA): University of Washington, Seattle; 2020. Available from: https://www.ncbi.nlm.nih.gov/books/NBK169825/ 13. Becker M, Mastropasqua F, Reising JP, Maier S, Ho ML, Rabkina I, et al. Presynaptic dysfunction in CASK-related neurodevelopmental disorders. Transl Psychiatry. 2020 Sep 14;10(1):312. 14. Dubbs H, Ortiz-Gonzalez X, Marsh ED. Pathogenic variants in CASKI: Expanding the genotypephenotype correlations. Am J Med Genet A. 2022 Sep;188(9):2617-26. 15. Moog U, Bierhals T, Brand K, Bautsch J, Biskup S, Brune T, et al. Phenotypic and molecular insights into CASK-related disorders in males. Orphanet J Rare Dis. 2015 Dec;10(1):44. 16. Seto T, Hamazaki T, Nishigaki S, Kudo S, Shintaku H, Ondo Y, et al. A novel CASK mutation identified in siblings exhibiting developmental disorders with/without microcephaly. Intractable Rare Dis Res. 2017;6(3):177-82. 17. LaConte LEW, Chavan V, Elias AF, Hudson C, Schwanke C, Styren K, et al. Two microcephalyassociated novel missense mutations in CASK specifically disrupt the CASK-neurexin interaction. Hum Genet. 2018 Mar;137(3):231-46. 18. LaConte LEW, Chavan V, DeLuca S, Rubin K, Malc J, Berry S, et al. An N-terminal heterozygous missense CASK mutation is associated with microcephaly and bilateral retinal dystrophy plus optic nerve atrophy. Am J Med Genet A. 2019 Jan;179(1):94-103. 19. Burglen L, Chantot-Bastaraud S, Garel C, Milh M, Touraine R, Zanni G, et al. Spectrum of pontocerebellar hypoplasia in 13 girls and boys with CASK mutations: confirmation of a recognizable phenotype and first description of a male mosaic patient. Orphanet J Rare Dis.

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490 20. Moog U, Kutsche K, Kortum F, Chilian B, Bierhals T, Apeshiotis N, et al. Phenotypic spectrum 491 associated with CASK loss-of-function mutations. J Med Genet. 2011 Nov 1;48(11):741-51. 492 21. Giacomini T, Nuovo S, Zanni G, Mancardi MM, Cusmai R, Pepi C, et al. CASK related disorder: 493 Epilepsy and developmental outcome. Eur J Paediatr Neurol. 2021 Mar;31:61-9. 494 22. Mori T, Zhou M, Tabuchi K. Diverse Clinical Phenotypes of CASK-Related Disorders and Multiple 495 Functional Domains of CASK Protein. Genes. 2023 Aug 20;14(8):1656. 496 23. Lindsay N, Runicles A, Johnson MH, Jones EJH, Bolton PF, Charman T, et al. Early development 497 and epilepsy in tuberous sclerosis complex: A prospective longitudinal study. Dev Med Child 498 Neurol. 2024 May;66(5):635-43. 499 24. Tye C, Mcewen FS, Liang H, Underwood L, Woodhouse E, Barker ED, et al. Long-term cognitive 500 outcomes in tuberous sclerosis complex. Dev Med Child Neurol. 2020 Mar;62(3):322-9. 501 25. Bar C. Breuillard D. Kuchenbuch M. Jennesson M. Le Guvader G. Isnard H. et al. Adaptive 502 behavior and psychiatric comorbidities in KCNB1 encephalopathy. Epilepsy Behav. 2022 503 Jan;126:108471. 504 26. Levy T, Gluckman J, Siper PM, Halpern D, Zweifach J, Filip-Dhima R, et al. Clinical, genetic, and 505 cognitive correlates of seizure occurrences in Phelan-McDermid syndrome. J Neurodev Disord. 506 2024 May 10;16(1):25. 507 27. Takanashi J, Okamoto N, Yamamoto Y, Hayashi S, Arai H, Takahashi Y, et al. Clinical and 508 radiological features of Japanese patients with a severe phenotype due to CASK mutations. Am J

509

510 28. Valayannopoulos V, Michot C, Rodriguez D, Hubert L, Saillour Y, Labrune P, et al. Mutations of 511 TSEN and CASK genes are prevalent in pontocerebellar hypoplasias type 2 and 4. Brain. 2012 Jan 512 1;135(1):e199-e199. 513 29. Sparrow SS, Cicchetti DV, Saulnier, CA. Vineland adaptive behavior scales: Third edition 514 (Vineland-3). Bloomington: NCS Pearson.; 2016. 515 30. Ortibus E, Laenen A, Verhoeven J, De Cock P, Casteels I, Schoolmeesters B, et al. Screening for 516 Cerebral Visual Impairment: Value of a CVI Questionnaire. Neuropediatrics. 2011 517 Aug;42(04):138-47. 518 31. Constantino JN, Gruber CP. Social Responsiveness Scale-Second Edition (SRS-2). Torrance, CA: 519 Western Psychological Services.; 2012. 520 32. Einfeld SL, Tonge BJ. The Developmental Behavior Checklist: The development and validation of 521 an instrument to assess behavioral and emotional disturbance in children and adolescents with 522 mental retardation. J Autism Dev Disord. 1995 Apr;25(2):81-104. 523 33. Moss J. Oliver C. The Repetitive Behaviour Scale. Manual for administration and scorer 524 interpretation. Birmingham, UK: University of Birmingham.; 2008. 525 34. Lee NR, Niu X, Zhang F, Clasen LS, Kozel BA, Smith ACM, et al. Variegation of autism related traits 526 across seven neurogenetic disorders. Transl Psychiatry. 2022 Apr 7;12(1):149. 527 35. Lubbers K, Stijl EM, Dierckx B, Hagenaar DA, Ten Hoopen LW, Legerstee JS, et al. Autism 528 Symptoms in Children and Young Adults With Fragile X Syndrome, Angelman Syndrome, 529 Tuberous Sclerosis Complex, and Neurofibromatosis Type 1: A Cross-Syndrome Comparison.

530

Front Psychiatry. 2022 May 16;13:852208.

531 36. Hyman P. Oliver C. Hall S. Self-injurious behavior, self-restraint, and compulsive behaviors in 532 Cornelia de Lange syndrome. Am J Ment Retard. 2002;107(2):146-54. 533 37. Arron K, Oliver C, Moss J, Berg K, Burbidge C. The prevalence and phenomenology of self-534 injurious and aggressive behaviour in genetic syndromes: Self-injurious behaviour in genetic 535 syndromes. J Intellect Disabil Res. 2011 Feb;55(2):109-20. 536 38. Eden KE, de Vries PJ, Moss J. Self-injury and aggression in tuberous sclerosis complex: cross 537 syndrome comparison and associated risk markers. J Neurodev Disord [Internet]. 2014;6(10). 538 Available from: https://doi.org/10.1186/1866-1955-6-10 539 39. Bissell S, Oliver C, Moss J, Heald M, Waite J, Crawford H, et al. The behavioural phenotype of 540 SATB2-associated syndrome: a within-group and cross-syndrome analysis. J Neurodev Disord. 541 2022 Dec;14(1):25. 542 40. Dunn W, Little LM, Dean E, Robertson S, Evans B. The Sensory Profile 2: Short Sensory Profile. 543 2nd ed. Pearson; 2014. 544 41. Agar G. Brown C. Sutherland D. Coulborn S. Oliver C. Richards C. Sleep disorders in rare genetic 545 syndromes: a meta-analysis of prevalence and profile. Mol Autism. 2021;12(1):1-17. 546 42. Surtees ADR, Oliver C, Jones CA, Evans DL, Richards C. Sleep duration and sleep quality in people 547 with and without intellectual disability: A meta-analysis. Sleep Med Rev. 2018 Aug;40:135-50. 548 43. Tietze AL, Blankenburg M, Hechler T, Michel E, Koh M, Schlüter B, et al. Sleep disturbances in 549 children with multiple disabilities. Sleep Med Rev. 2012 Apr;16(2):117-27. 550 44. Pearson EV, Waite J, Oliver C. Differences in the Information Needs of Parents With a Child With 551 a Genetic Syndrome: A Cross-Syndrome Comparison. J Policy Pract Intellect Disabil.

552

2018;15(2):94-100.

553

554

555

556

557

558

559

560

561

562

563

564

565

566

567

568

569

570

571

572

573

574

45. Trickett J, Heald M, Oliver C. Sleep in children with Angelman syndrome: Parental concerns and priorities. Res Dev Disabil. 2017 Oct;69:105-15. 46. Cohen S, Fulcher BD, Rajaratnam SMW, Conduit R, Sullivan JP, Hilaire MAS, et al. Behaviorallydetermined sleep phenotypes are robustly associated with adaptive functioning in individuals with low functioning autism. Sci Rep. 2017 Oct 27;7(1):14228. 47. Brooks Ц, Olsen MN, Bacevice AM, Beebe A, Konstantinopoulou S, Taylor HG. Relationship between sleep, sleep apnea, and neuropsychological function in children with Down syndrome. Sleep Breath. 2015 Mar; 19(1):197-204. 48. Rzepecka H, McKenzie K, McClure I, Murphy S. Sleep, anxiety and challenging behaviour in children with intellectual disability and/or autism spectrum disorder. Res Dev Disabil. 2011 Nov;32(6):2758-66. 49. Cohen S, Fulcher BD, Rajaratnam SMW, Conduit R, Sullivan JP, St Hilaire MA, et al. Sleep patterns predictive of daytime challenging behavior in individuals with low-functioning autism. Autism Res. 2018 Feb;11(2):391-403. 50. Coleman H, Mannion A, Whelan S, Tones M, Heussler H, Bellgard M, et al. Association Between Challenging Behaviour and Sleep Problems in Adults Enrolled in the Global Angelman Syndrome Registry. J Autism Dev Disord [Internet]. 2024 May 20 [cited 2024 Sep 18]; Available from: https://link.springer.com/10.1007/s10803-024-06367-6 51. John A, Ng-Cordell E, Hanna N, Brkic D, Baker K. The neurodevelopmental spectrum of synaptic vesicle cycling disorders. J Neurochem. 2021;157(2):208-28. 52. Shaw E, Flitcroft I, Bowman R, Baker K. Cerebral visual impairment: genetic diagnoses and

phenotypic associations. J Med Genet. 2024 Jun;61(6):605–12.

575

576

577

578

579

580

581

582

583

584

585

586

587

588

589

53. Besag FMC, Vasey MJ. Neurocognitive Effects of Antiseizure Medications in Children and Adolescents with Epilepsy. Pediatr Drugs. 2021 May;23(3):253-86. 54. Strzelczyk A, Schubert-Bast S. Psychobehavioural and Cognitive Adverse Events of Anti-Seizure Medications for the Treatment of Developmental and Epileptic Encephalopathies. CNS Drugs. 2022 Oct;36(10):1079-111. 55. Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, Guilhoto L, et al. ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017 Apr;58(4):512-21. 56. Ben Itzhak N, Vancleef K, Franki I, Laenen A, Wagemans J, Ortibus E. Visuoperceptual profiles of children using the Flemish cerebral visual impairment questionnaire. Dev Med Child Neurol. 2020 Aug;62(8):969-76. 57. Crotti M, Ortibus E, Mailleux L, Decraene L, Kleeren L, Itzhak NB. Visual, perceptual functions, and functional vision in children with unilateral cerebral palsy compared to children with neurotypical development. Dev Med Child Neurol. 2024 Aug;66(8):1084-95.

590

591

592

593

594

595

596

597

598

599

600

601

602

603

604

605

606

607

608

609

Figure legends Figure 1. Vineland Adaptive Behaviour Scales - age standardised scores within the BINGO CASKrelated disorder group. Legend: ID severity cut-offs are overlaid in red and annotated in black for the VABS composite score. Mean scores on each measure are represented by the black diamond. Figure 2. Social Responsiveness Scale - T-scores within the BINGO CASK-related disorder group. Legend: Severity cut-offs are overlaid in red and annotated in black for the SRS-2 total score. Mean scores on each measure are represented by the black diamond. Figure 3. Developmental Behaviour Checklist - T-scores within the BINGO CASK-related disorder group. . Legend: Levels of concern are overlaid in red and annotated in black for all DBC2 measures. Mean scores on each measure are represented by the black diamond. Figure 4. Restricted and repetitive Behaviour Questionnaire – Scores within the BINGO CASK-related disorder group. Legend: Severity cut-offs are overlaid in red and annotated in black for all RBQ measures. Mean scores on each measure are represented by the black diamond. Figure 5. Flemish cerebral visual impairment questionnaire — Factors scores within the BINGO CASKrelated disorder group. Legend: Mean scores for children with CVI (taken from 32) are overlaid in red, and mean scores for children with CVI and unilateral (taken from 33) are overlaid in blue. Mean scores on each measure for the BINGO CASK-related group are represented by the black diamond. Figure 6. Correlations between demographic and neurodevelopmental domains within CASK-related disorder.

Table 1. Comparison between reviewed cases and BINGO CASK-related disorder group.

610

Characteristics (Total; n (%))	Reviewed Cases	BINGO Participants
Sample details		
Sample size	151	31
Females	109 (72.2)	27 (87.1)
Age: range (mean) / months ^a	0.5-588	36-310 (118.8)
Genetic details		
SNV	108/151 (71.5)	20/27 (74.1)
Truncating	47/108 (43.5)	13/20 (65.0)
Missense	38/108 (35.2)	2/20 (10.0)
Intronic	22/108 (20.4)	5/20 (25.0)
CNV	43/151 (28.5)	7/27 (25.9)
Intragenic	28/43 (65.1)	6/7 (85.7)
Multi-gene	14/43 (32.6)	1/7 (14.3)
Uncertain	1/43 (2.3)	0/7 (0.0)
Inheritance		
De novo	68/88 (77.3)	12/15 (80.0)
Inherited	20/88 (22.7)	3/15 (20.0)
Feeding difficulties	56/98 (57.1)	26/31 (83.9)
Tone abnormalities		
Hypotonia	64/112 (57.1)	13/31 (41.9)
Hypertonia	38/91 (41.8)	6/31 (19.4)
Mixed	8/57(14.0)	7/31 (22.6)
OA		
Optic atrophy	32/112 (28.6)	3/31 (9.7)
Strabismus	34/112 (30.4)	8/31 (25.8)
Nystagmus	28/112 (25)	1/31 (3.2)
Other	30/78 (38.5)	18/31 (58.1)
SNHL	28/114 (24.6)	7/31 (22.6)
Seizures	66/135 (48.9)	11/31 (35.5)
<i>DD/</i> ID ^b		
Mild/moderate	13/108 (12.0)	17/28 (60.7)
Severe	81/108 (75.0)	7/28 (25.0)
Profound	14/108 (13.0)	4/28 (14.3)
Developmental milestones		
Able to sit	64/113 (56.6)	27/31 (87.1)
Age acquired / months	6-36	7-36
Able to walk	26/101 (25.7)	16/31 (51.6)
Age acquired / months	18-72	13-108
Verbal abilities	23/68 (33.8)	14/31 (45.2)
Brain abnormalities ^c		
MICPCH	121/139 (87.1)	11/25 (44.0)
CH and/or PH only	5/139 (3.6)	1/25 (4.0)
MIC and other	4/139 (2.9)	1/25 (4.0)
MIC and CH	3/139 (2.1)	1/25 (4.0)
MIC only	3/139 (2.1)	8/25 (32.0)
Other abnormalities only	0/139 (0.0)	1/25 (4.0)
No abnormalities	3/139 (2.1)	2/25 (8.0)

single nucleotide variant.

Absolute frequencies of clinical information are reported with the denominator indicating the number of individuals for whom information was available.

^a The mean age of individuals in previous papers was not possible to calculate.

^b DD/ID was reported in previous papers using medical reports. In current study, VABS composite categorised as 'mild/moderate', 'severe' and 'profound' to align with previously reported classifications was used as a proxy measure of severity of DD/ID.

^c In previous papers, we reported cases where MRI reports were available. In current study, information about microcephaly and structural brain abnormalities were obtained via MRI, genetic and parental reports.

Abbreviations:

CH: cerebellar hypoplasia; CNV: copy number variant; DD/ID: developmental delay or intellectual disability; MIC: microcephaly; MICPCH: microcephaly with pontine and cerebellar hypoplasia; OA: Ophthalmological Abnormalities; PH: pontine hypoplasia; SNHL: sensorineural hearing loss; SNV:











